摘要
目的从体内和体外实验,观察中药消岩汤联合重组人内皮血管抑制素配合5-Fu对乳腺癌的治疗效果及作用机制。方法体外实验分为空白组、不同中药浓度及联合重组人内皮血管抑制素配合5-Fu组共10组,作用24h后,以MTT法检测MCF-7乳腺癌细胞的细胞增殖活性及用Hoechst33258法检测细胞的凋亡情况。体内实验分为空白对照组、消岩汤高剂量组、消岩汤低剂量组、5-Fu组、消岩汤高剂量+5-Fu组和消岩汤高剂量+重组人内皮血管抑制素+5-Fu组,分别予以干预措施,干预7天后处死,观察抑瘤率,小鼠体重变化及血清中瘦素水平变化。结果与对照组相比,各用药组均能不同程度地抑制细胞活性和促进凋亡,抑制肿瘤细胞增长,增加荷瘤小鼠体重,降低血清中瘦素水平含量,减少肿瘤周围新生血管生成,消岩汤联合重组人内皮血管抑制素及5-Fu组最优。结论消岩汤对重组人内皮血管抑制素配合化疗治疗乳腺癌有增效减毒作用。
Objective To observe the effectiveness of Chinese Xiaoyan compound recipe associated with endostar and 5-Fu in treating mice with breast cancer. Methods In vitro, mice were divided into blank group, Xiaoyan compound recipe （XCR） group, and XCR combined with endostar and 5-Fu group. After24h of treatment cell multiplication and Hoechst 33258 to cell apoptosis of MCF-7 was measured using MTT. In vivo, mice were divided into blank group, XCR groups and XCR combined with endostar and 5-Fu groups. After 7 days, the differences of tumor volume, weight and leptin level in serum were compared. Results Compare with the control group, in groups treated with XCR, cytostatie activity and apoptosis were significantly inhibited, the serum leptin level significantly decreased, and new vessels around tumors significantly decreased. Conclusion XCR is effective in treating breast cancer in mice, especially when combined with endostar and 5-Fu.
出处
《癌症进展》
2011年第3期336-342,共7页
Oncology Progress
